Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. LAL PATHLABS Gains 4%; BSE HEALTHCARE Index Up 2.0%
Wed, 7 Aug 16:5

DR. LAL PATHLABS Gains 4%; BSE HEALTHCARE Index Up 2.0%Image source: Sakorn BernardaSv/www.istockphoto.com

DR. LAL PATHLABS share price has zoomed 4% and is presently trading at Rs 3,340.0.

Meanwhile, the BSE HEALTHCARE index is at 40,821.0 (up 2.0%).

Among the top gainers in the BSE HEALTHCARE index today are AJANTA PHARMA (up 5.4%) and Natco Pharma (up 5.2%).

GLAND PHARMA (down 4.0%) and FORTIS HEALTHCARE (down 2.1%) are among the top losers today.

Over the last one year, DR. LAL PATHLABS has moved up from Rs 2,373.2 to Rs 3,340.0, registering a gain of Rs 966.8 (up 40.7%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,300.0 to 40,821.0, registering a gain of 44.2% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 115.6%), GRANULES INDIA (up 105.0%) and SUVEN PHARMACEUTICALS (up 101.9%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 79,468.0 (up 1.1%).

The top gainers among the BSE Sensex today are MUNDRA PORT & SEZ (up 3.5%) and Power Grid Corp. (up 3.2%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.

In the meantime, NSE Nifty is at 24,315.3 (up 1.4%). ONGC and Coal India are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,953.5 to 79,468.0, registering a gain of 13,514.5 points (up 20.5%).

DR. LAL PATHLABS Financial Update...

DR. LAL PATHLABS net profit grew 50.8% YoY to Rs 858 million for the quarter ended March 2024, compared to a profit of Rs 569 million a year ago. Net sales rose 11.1% to Rs 5,454 million during the period as against Rs 4,910 million in January-March 2023.

For the year ended March 2024, DR. LAL PATHLABS reported 50.3% increase in net profit to Rs 3,623 million compared to net profit of Rs 2,411 million during FY23. Revenue of the company grew 10.4% to Rs 22,266 million during FY24.

The current Price to earnings ratio of DR. LAL PATHLABS, based on rolling 12 month earnings, stands at 77.0.


Equitymaster requests your view! Post a comment on "DR. LAL PATHLABS Gains 4%; BSE HEALTHCARE Index Up 2.0%". Click here!